table of contents section para no.
counsel for the second respondent (alphapharm pty ltd): mr dk catterns qc, mr s burley sc and mr js cooke solicitor for the second respondent (alphapharm pty ltd): mallesons stephen jaques dates of hearing: 11, 12, 13, 16, 17, 18, 19, 23, 24, 26 april 2007; 1, 7, 8, 9, 10, 11 may 2007 date last written submission received: 21 november 2007 date of judgment: 24 april 2008 austlii: copyright policy | disclaimers | privacy policy | feedback url: http://www.austlii.edu.au/au/cases/cth/fca/2008/559.html
a introduction and background [1] --- [78] b the patent [79] --- [113] c construction of the patent [114] --- [153] d novelty [154] --- [174] e obviousness [175] --- [426] f manner of manufacture --- s 18(1)(a) of the act [427] --- [441] g lack of definition --- s 40(2)(b) of the act [442] --- [447] h lack of fair basing --- s 40(3) of the act [448] --- [460] i lack of clarity --- s 40(3) of the act [461] --- [465] j inutility --- s 18(1)(c) of the act [466] --- [474] k the lundbeck appeal (extension of term) proceeding --- alphapharm's and arrow's claims for rectification under s 192 of the act [475] --- [544] l the tga (protected information) proceeding [545] --- [633] m infringement by alphapharm [634] --- [697] n admissibility of certain evidence [698] --- [783] o conclusion [784] --- [785] section a --- introduction and background general these four proceedings, which were heard together, relate to australian patent no 623144 (the patent or the australian escitalopram patent) held by h lundbeck a/s (lundbeck), a danish pharmaceutical company.